Logo Logo
Hilfe
Hilfe
Switch Language to English

Wang, Hui-fang; Wang, Yi-xuan; Zhou, Yu-ping; Wei, Yun-peng; Yan, Yi; Zhang, Ze-jian und Jing, Zhi-cheng (2022): Protein O-GlcNAcylation in cardiovascular diseases. In: Acta Pharmacologica Sinica, Bd. 44, Nr. 1: S. 8-18

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

O-GlcNAcylation is a post-translational modification of protein in response to genetic variations or environmental factors, which is controlled by two highly conserved enzymes, i.e. O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA). Protein O-GlcNAcylation mainly occurs in the cytoplasm, nucleus, and mitochondrion, and it is ubiquitously implicated in the development of cardiovascular disease (CVD). Alterations of O-GlcNAcylation could cause massive metabolic imbalance and affect cardiovascular function, but the role of O-GlcNAcylation in CVD remains controversial. That is, acutely increased O-GlcNAcylation is an adaptive heart response, which temporarily protects cardiac function. While it is harmful to cardiomyocytes if O-GlcNAcylation levels remain high in chronic conditions or in the long run. The underlying mechanisms include regulation of transcription, energy metabolism, and other signal transduction reactions induced by O-GlcNAcylation. In this review, we will focus on the interactions between protein O-GlcNAcylation and CVD, and discuss the potential molecular mechanisms that may be able to pave a new avenue for the treatment of cardiovascular events.

Dokument bearbeiten Dokument bearbeiten